Phuturdex › Diseases › Pulmonary fibrosis
Drugs in development · updated 30 October 2026
Pulmonary fibrosis: drugs in development
As of 30 October 2026 there are 29 active clinical trials (recruiting or ongoing, phases I–III) on 34 drugs for pulmonary fibrosis. 16 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| BMS-986278 | III | 3 | NCT07441408 |
| Deupirfenidone | III | 2 | NCT07284602 |
| SC1011 | II–III | 1 | NCT06125327 |
| [68Ga]CBP8 | II | 3 | NCT07572383 |
| [18F]FAPI-74 | I–II | 1 | NCT07705074 |
| AP01 | II | 1 | NCT06329401 |
| CD19 | I–II | 1 | NCT03500731 |
| ENV-101 | II | 1 | NCT06422884 |
| Hymecromone | II | 1 | NCT06325696 |
| INS018_055 | II | 1 | NCT05975983 |
| Nicotinamide ribosideNicotinamide ribonucleoside | II | 1 | NCT06567717 |
| of 68Ga-NI-FAPI | I–II | 1 | NCT07464132 |
| PIPE-791 | II | 1 | NCT07284459 |
| Senicapoc | II | 1 | NCT06714123 |
| 68Ga-FAPI | I | 1 | NCT05121779 |
| 68Ga-FAPI-46 | Early I | 1 | NCT05365802 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PirfenidoneEsbriet®, Pirfenidone Viatris® | III | 3 | NCT07284602 |
| SirolimusRapamycin, Scomara® | II–III | 1 | NCT04948203 |
| Gadoterate MeglumineDotarem | II | 2 | NCT07572383 |
| AlemtuzumabCampath, Lemtrada® | I–II | 1 | NCT03500731 |
| AmitriptylineElavil® | II | 1 | NCT05120934 |
| BelumosudilRezurock® | II | 1 | NCT06751602 |
| DuloxetineDrizalma Sprinkle®, Cymbalta® | II | 1 | NCT05120934 |
| FingolimodGilenya®, Fingolimod Accord® | II | 1 | NCT05285878 |
| FludarabineFludara, FLUDARABIN | I–II | 1 | NCT03500731 |
| HydroxyureaHydroxycarbamide, Hydroxycarbamid | I–II | 1 | NCT03500731 |
| NintedanibNintedanib Accord®, Vargatef® | II | 1 | NCT07679893 |
| RituximabRuxience, Rituxan | I–II | 1 | NCT03500731 |
| ThiotepaTepylute®, Tepadina And Sodium Chloride® | I–II | 1 | NCT03500731 |
| ZincWilzin® | II | 1 | NCT06567717 |
| 18F-FDG^1^8F-fluorodeoxyglucose, Fludeoxyglucose F-18 | I | 1 | NCT05121779 |
Sorted by most advanced phase and number of active trials. Showing 15 of 18 drugs.
All 34 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Idiopathic pulmonary fibrosis 57 drugs
- Interstitial lung disease 65 drugs
- Cough 14 drugs
- Fibrosis 52 drugs
- Adjustment disorder 3 drugs
- Neoplasm 671 drugs
- Amyotrophic lateral sclerosis 79 drugs
- Multiple sclerosis 93 drugs
- Depression 73 drugs
- Anxiety disorder 32 drugs
- Chronic cough 9 drugs
- Obesity 233 drugs
Broader categories
- Respiratory disease 57 drugs
- Lung disease 104 drugs
- Fibrosis 52 drugs
- Interstitial lung disease 65 drugs
- Hypersensitivity 22 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D011658 “Pulmonary Fibrosis”.